⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309465 | 1.00 | — | — | |
| SCHEMBL5357862 | 1.00 | — | — | |
| SCHEMBL9609392 | 0.80 | CYP1A2 (0.33) | — | |
| SCHEMBL28701038 | 0.77 | MAPK1 (0.35) | — | |
| SCHEMBL4469424 | 0.75 | — | — | |
| SCHEMBL6512787 | 0.75 | — | — | |
| SCHEMBL5930875 | 0.73 | — | — | |
| SCHEMBL441789 | 0.73 | — | — | |
| SCHEMBL443754 | 0.73 | — | — | |
| SCHEMBL195392 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2145547-B1 | Increased stability of flavor compounds | KRAFT FOODS R & D INC (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20100015276-A1 | Increased Stability Of Flavor Compounds | KRAFT FOODS R&D, INC. | 2010-01-21 | — | — | US | disclosed |
| US-20100015276-A1 | Increased Stability Of Flavor Compounds | KRAFT FOODS R&D, INC. | 2010-01-21 | — | — | US | disclosed |
| US-RE39464-E1 | Oligonucleolotides having site specific chiral phosphorothioate internucleoside linkages | ISIS PHARMACEUTICALS INC. (US) | 2007-01-09 | — | — | US | disclosed |
| EP-1097162-B1 | OLIGONUCLEOTIDES HAVING SITE SPECIFIC CHIRAL PHOSPHOROTHIOATE INTERNUCLEOSIDE LINKAGES | ISIS PHARMACEUTICALS INC (US) | 2006-01-18 | — | — | EP | disclosed |
| US-6867294-B1 | Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages | ISIS PHARMACEUTICALS, INC. (US) | 2005-03-15 | — | — | US | disclosed |
| US-6440943-B1 | MIMIC AND/OR MODULATE THE ACTIVITY OF WILD-TYPE NUCLEIC ACIDS; THE 5' AND THE 3'-TERMINAL INTERNUCLEOSIDE LINKAGES ARE CHIRALLY SP AND INTERNAL INTERNUCLEOSIDE LINKAGES ARE CHIRALLY RP; RESISTANT TO NUCLEASE DEGRADATION; PSORIASIS | ISIS PHARMACEUTICALS, INC. | 2002-08-27 | — | — | US | disclosed |
| EP-1097162-A4 | OLIGONUCLEOTIDES HAVING SITE SPECIFIC CHIRAL PHOSPHOROTHIOATE INTERNUCLEOSIDE LINKAGES | ISIS PHARMACEUTICALS INC (US) | 2002-03-06 | — | — | EP | disclosed |
| WO-2001040515-A1 | GAPPED OLIGOMERS HAVING SITE SPECIFIC CHIRAL PHOSPHOROTHIOATE INTERNUCLEOSIDE LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| EP-1097162-A2 | OLIGONUCLEOTIDES HAVING SITE SPECIFIC CHIRAL PHOSPHOROTHIOATE INTERNUCLEOSIDE LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 2001-05-09 | — | — | EP | disclosed |
| WO-2000004034-A2 | OLIGONUCLEOTIDES HAVING SITE SPECIFIC CHIRAL PHOSPHOROTHIOATE INTERNUCLEOSIDE LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 2000-01-27 | — | — | WO | disclosed |